Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Aging (Albany NY) ; 15(13): 5966-5989, 2023 07 12.
Article in English | MEDLINE | ID: mdl-37437248

ABSTRACT

A hallmark of eukaryotic aging is a loss of epigenetic information, a process that can be reversed. We have previously shown that the ectopic induction of the Yamanaka factors OCT4, SOX2, and KLF4 (OSK) in mammals can restore youthful DNA methylation patterns, transcript profiles, and tissue function, without erasing cellular identity, a process that requires active DNA demethylation. To screen for molecules that reverse cellular aging and rejuvenate human cells without altering the genome, we developed high-throughput cell-based assays that distinguish young from old and senescent cells, including transcription-based aging clocks and a real-time nucleocytoplasmic compartmentalization (NCC) assay. We identify six chemical cocktails, which, in less than a week and without compromising cellular identity, restore a youthful genome-wide transcript profile and reverse transcriptomic age. Thus, rejuvenation by age reversal can be achieved, not only by genetic, but also chemical means.


Subject(s)
Cellular Reprogramming , Induced Pluripotent Stem Cells , Animals , Humans , Cellular Reprogramming/genetics , Cellular Senescence/genetics , Aging/genetics , DNA Methylation , Mammals
2.
Epigenetics Chromatin ; 15(1): 6, 2022 02 04.
Article in English | MEDLINE | ID: mdl-35120578

ABSTRACT

BACKGROUND: Mammalian dosage compensation is achieved by the inactivation of one X chromosome in XX individuals. In eutheria this process is initiated early in development by the long non-coding RNA XIST. Studies of the initiation of silencing by XIST have focussed on mouse models, so the domains of XIST required to induce silencing in humans, and their relationship with domains required to establish heterochromatin remain to be determined. METHODS: We have previously established an inducible XIST cDNA in somatic cells and shown it can induce silencing and recruit heterochromatic features. We now assess a series of deletions across the transgene for the ability to induce silencing and integrate these results with time-course and chromatin-remodelling inhibitor treatments to follow the steps of XIST-induced silencing and heterochromatinization. DISCUSSION: We find that in addition to the previously reported necessity of the 5' A repeat region for XIST-induced silencing, the 1 kb around the small F repeat region and a non-repetitive region at the 3' end of the RNA are also required to silence genes. Silencing of genes up to 17 Mb from the XIST integration occurs within 2 days, while formation of a Cot-1 depleted domain is slower, and more dependent on the region encompassing Repeat F. The role of this region encompassing Repeat F in both the silencing of actively transcribed genes, the spread of H3K27me3 and the formation of a transcriptionally inert domain suggests a role in a pathway crucial for the spread of XIST across the chromatin to target distal regions of inactivation. Histone deacetylation requires only the A repeat region, with HDAC3 inhibition showing limited effect on silencing, but an impact on H3K27me3 recruitment, and as a result the recruitment of MacroH2A. Global HDAC inhibition impacted silencing in both a distance and dose-dependent fashion. The E repeat region was required for CIZ1 and H4K20me1 recruitment as well as H3K27me3; however, these appeared to act relatively independently. The H3K27me3 mark established by PRC2 integrated silencing and many of the heterochromatic features, while the PRC1 mark ubH2A appeared to be downstream of silencing in these human somatic cells.


Subject(s)
Heterochromatin , Histones , Animals , Chromatin , Chromatin Assembly and Disassembly , Gene Silencing , Heterochromatin/genetics , Humans , Mammals , Mice , Nuclear Proteins , RNA, Long Noncoding
3.
J Nutr Biochem ; 98: 108815, 2021 12.
Article in English | MEDLINE | ID: mdl-34242723

ABSTRACT

Transcription factor (TF)-mediated regulation of genes is often disrupted during carcinogenesis. The DNA methylation state of TF-binding sites may dictate transcriptional activity of corresponding genes. Stilbenoid polyphenols, such as pterostilbene (PTS), have been shown to exert anticancer action by remodeling DNA methylation and gene expression. However, the mechanisms behind these effects still remain unclear. Here, the dynamics between oncogenic TF OCT1 binding and de novo DNA methyltransferase DNMT3B binding in PTS-treated MCF10CA1a invasive breast cancer cells has been explored. Using chromatin immunoprecipitation (ChIP) followed by next generation sequencing, we determined 47 gene regulatory regions with decreased OCT1 binding and enriched DNMT3B binding in response to PTS. Most of those genes were found to have oncogenic functions. We selected three candidates, PRKCA, TNNT2, and DANT2, for further mechanistic investigation taking into account PRKCA functional and regulatory connection with numerous cancer-driving processes and pathways, and some of the highest increase in DNMT3B occupancy within TNNT2 and DANT2 enhancers. PTS led to DNMT3B recruitment within PRKCA, TNNT2, and DANT2 at loci that also displayed reduced OCT1 binding. Substantial decrease in OCT1 with increased DNMT3B binding was accompanied by PRKCA promoter and TNNT2 and DANT2 enhancer hypermethylation, and gene silencing. Interestingly, DNA hypermethylation of the genes was not detected in response to PTS in DNMT3B-CRISPR knockout MCF10CA1a breast cancer cells. It indicates DNMT3B-dependent methylation of PRKCA, TNNT2, and DANT2 upon PTS. Our findings provide a better understanding of mechanistic players and their gene targets that possibly contribute to the anticancer action of stilbenoid polyphenols.


Subject(s)
Breast Neoplasms/genetics , DNA (Cytosine-5-)-Methyltransferases/metabolism , DNA Methylation/drug effects , Oncogenes/genetics , Organic Cation Transporter 1/metabolism , Stilbenes/pharmacology , Antineoplastic Agents/pharmacology , Breast Neoplasms/metabolism , Cell Line, Tumor , Chromatin Immunoprecipitation/methods , Female , Gene Expression Regulation, Neoplastic , Gene Silencing , Humans , Promoter Regions, Genetic , Stilbenes/metabolism , DNA Methyltransferase 3B
4.
PLoS Genet ; 17(3): e1009123, 2021 03.
Article in English | MEDLINE | ID: mdl-33750950

ABSTRACT

XIST establishes inactivation across its chromosome of origin, even when expressed from autosomal transgenes. To identify the regions of human XIST essential for recruiting heterochromatic marks we generated a series of overlapping deletions in an autosomal inducible XIST transgene present in 8p of the HT1080 male fibrosarcoma cell line. We examined the ability of each construct to enrich its unified XIST territory with the histone marks established by PRC1 and PRC2 as well as the heterochromatin factors MacroH2A and SMCHD1. Chromatin enrichment of ubH2A by PRC1 required four distinct regions of XIST, and these were completely distinct from the two domains crucial for enrichment of H3K27me3 by PRC2. Both the domains required, as well as the impact of PRC1 and PRC2 inhibitors, suggest that PRC1 is required for SMCHD1 while PRC2 function is necessary for MacroH2A recruitment, although incomplete overlap of regions implicates roles for additional factors. This cooperativity between factors contributes to the requirement for multiple separate domains being required for each feature examined. The independence of the PRC1/PRC2 pathways was observed when XIST was expressed both autosomally or from the X chromosome suggesting that these observations are not purely a result of the context in which XIST operates. Although independent domains were required for the PRC1 and PRC2 pathways overall all regions tested were important for some aspect of XIST functionality, demonstrating both modularity and cooperativity across the XIST lncRNA.


Subject(s)
Cell Cycle Proteins/metabolism , Gene Expression Regulation , RNA, Long Noncoding/genetics , Cell Cycle Proteins/chemistry , Cell Line , Chromosomes, Human, X , Heterochromatin/genetics , Heterochromatin/metabolism , Histones/genetics , Histones/metabolism , Humans , Models, Biological , Polycomb-Group Proteins/genetics , Protein Binding , RNA, Long Noncoding/metabolism , Repetitive Sequences, Nucleic Acid , Sequence Deletion
5.
Hum Mol Genet ; 27(R2): R242-R249, 2018 08 01.
Article in English | MEDLINE | ID: mdl-29701779

ABSTRACT

The X chromosome is unique in the genome. In this review we discuss recent advances in our understanding of the genetics and epigenetics of the X chromosome. The X chromosome shares limited conservation with its ancestral homologue the Y chromosome and the resulting difference in X-chromosome dosage between males and females is largely compensated for by X-chromosome inactivation. The process of inactivation is initiated by the long non-coding RNA X-inactive specific transcript (XIST) and achieved through interaction with multiple synergistic silencing pathways. Identification of Xist-interacting proteins has given insight into these processes yet the cascade of events from initiation to maintenance have still to be resolved. In particular, the initiation of inactivation in humans has been challenging to study as: it occurs very early in development; most human embryonic stem cell lines already have an inactive X; and the process seems to differ from mouse. Another difference between human and mouse X inactivation is the larger number of human genes that escape silencing. In humans over 20% of X-linked genes continue to be expressed from the otherwise inactive X chromosome. We are only beginning to understand how such escape occurs but there is growing recognition that escapees contribute to sexually dimorphic traits. The unique biology and epigenetics of the X chromosome have often led to its exclusion from disease studies, yet the X constitutes 5% of the genome and is an important contributor to disease, often in a sex-specific manner.


Subject(s)
Chromosomes, Human, X/genetics , Chromosomes, Human, X/metabolism , X Chromosome Inactivation/physiology , Animals , Chromosomes, Human, X/physiology , Female , Gene Silencing/physiology , Genes, Regulator/genetics , Genes, X-Linked/genetics , Genes, X-Linked/physiology , Humans , Male , Mice , RNA, Long Noncoding/genetics , X Chromosome/genetics , X Chromosome/metabolism , X Chromosome/physiology , X Chromosome Inactivation/genetics
6.
Biochem Cell Biol ; 94(1): 56-70, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26283003

ABSTRACT

During X-chromosome inactivation (XCI), nearly an entire X chromosome is permanently silenced and converted into a Barr body, providing dosage compensation for eutherians between the sexes. XCI is facilitated by the upregulation of the long non-coding RNA gene, XIST, which coats its chromosome of origin, recruits heterochromatin factors, and silences gene expression. During XCI, at least two distinct types of heterochromatin are established, and in this review we discuss the enrichment of facultative heterochromatin marks such as H3K27me3, H2AK119ub, and macroH2A as well as pericentric heterochromatin marks such as HP1, H3K9me3, and H4K20me3. The extremely stable maintenance of silencing is a product of reinforcing interactions within and between these domains. This paper "Xplores" the current knowledge of the pathways involved in XCI, how the pathways interact, and the gaps in our understanding that need to be filled.


Subject(s)
Gene Silencing , Histones/metabolism , Polycomb-Group Proteins/metabolism , RNA, Long Noncoding/metabolism , Sex Chromatin/metabolism , X Chromosome Inactivation , X Chromosome/genetics , Acetylation , Animals , DNA (Cytosine-5-)-Methyltransferases/metabolism , DNA Methylation , DNA-Binding Proteins/metabolism , Female , Histone Deacetylases/metabolism , Humans , Mice , RNA, Long Noncoding/genetics , Sex Chromatin/genetics , X Chromosome/metabolism
7.
Genome Biol ; 16: 208, 2015 Oct 02.
Article in English | MEDLINE | ID: mdl-26429547

ABSTRACT

BACKGROUND: X-chromosome inactivation is a striking example of epigenetic silencing in which expression of the long non-coding RNA XIST initiates the heterochromatinization and silencing of one of the pair of X chromosomes in mammalian females. To understand how the RNA can establish silencing across millions of basepairs of DNA we have modelled the process by inducing expression of XIST from nine different locations in human HT1080 cells. RESULTS: Localization of XIST, depletion of Cot-1 RNA, perinuclear localization, and ubiquitination of H2A occurs at all sites examined, while recruitment of H3K9me3 was not observed. Recruitment of the heterochromatic features SMCHD1, macroH2A, H3K27me3, and H4K20me1 occurs independently of each other in an integration site-dependent manner. Silencing of flanking reporter genes occurs at all sites, but the spread of silencing to flanking endogenous human genes is variable in extent of silencing as well as extent of spread, with silencing able to skip regions. The spread of H3K27me3 and loss of H3K27ac correlates with the pre-existing levels of the modifications, and overall the extent of silencing correlates with the ability to recruit additional heterochromatic features. CONCLUSIONS: The non-coding RNA XIST functions as a cis-acting silencer when expressed from nine different locations throughout the genome. A hierarchy among the features of heterochromatin reveals the importance of interaction with the local chromatin neighborhood for optimal spread of silencing, as well as the independent yet cooperative nature of the establishment of heterochromatin by the non-coding XIST RNA.


Subject(s)
Epigenesis, Genetic , Gene Silencing , RNA, Long Noncoding/genetics , X Chromosome Inactivation/genetics , Chromosomes, Human, X/genetics , Female , Gene Expression Regulation, Developmental , Genome, Human , Heterochromatin/genetics , Humans
8.
Eur J Neurosci ; 37(5): 743-56, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23351035

ABSTRACT

Signaling at nicotinic acetylcholine receptors in Caenorhabditis elegans controls many behaviors, including egg-laying and locomotor activity. Here, we show that C. elegans approaches a point source of nicotine in a time-, concentration- and age-dependent manner. Additionally, nicotine paired with butanone under starvation conditions prevented the reduced approach to butanone that is observed when butanone is paired with starvation alone and pairing with nicotine generates a preference for the tastes of either sodium or chloride over baseline. These results suggest nicotine acts as a rewarding substance in C. elegans. Furthermore, the nicotinic receptor antagonist mecamylamine, the smoking cessation pharmacotherapy varenicline, mutation of the dop-1 and dop-2 dopamine receptors, and mutations of either acr-5 or acr-15, two nicotinic receptor subunit genes with sequence homology to the mammalian α7 subunit, all reduced the nicotine approach behavior. These two mutants also were defective at associating the presence of nicotine with butanone under starvation conditions and acr-5 mutation could obviate the effect of pairing nicotine with salts. Furthermore, the approach deficit in acr-15 mutants was rescued by selective re-expression in a subset of neurons, but not in muscle. Caenorhabditis elegans may therefore serve as a useful model organism for nicotine-motivated behaviors that could aid in the identification of novel nicotine motivational molecular pathways and consequently the development of novel cessation aids.


Subject(s)
Behavior, Animal/drug effects , Caenorhabditis elegans Proteins/metabolism , Caenorhabditis elegans/physiology , Nicotine/pharmacology , Protein Subunits/metabolism , Receptors, Nicotinic/metabolism , Age Factors , Animals , Benzazepines/pharmacology , Butanones/pharmacology , Caenorhabditis elegans/drug effects , Caenorhabditis elegans/metabolism , Caenorhabditis elegans Proteins/genetics , Chemotaxis/drug effects , Chemotaxis/genetics , Chlorides/pharmacology , Fasting , Mecamylamine/pharmacology , Muscles , Mutation , Neurons/metabolism , Nicotinic Agonists/pharmacology , Nicotinic Antagonists/pharmacology , Protein Subunits/genetics , Quinoxalines/pharmacology , Receptors, Dopamine D1/genetics , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/genetics , Receptors, Dopamine D2/metabolism , Receptors, Nicotinic/genetics , Reward , Sodium/pharmacology , Taste , Time Factors , Varenicline
SELECTION OF CITATIONS
SEARCH DETAIL
...